Log in

NASDAQ:THOR - Synthorx Stock Price, Forecast & News

$25.03
+0.05 (+0.20 %)
(As of 12/6/2019 04:00 PM ET)
Today's Range
$23.73
Now: $25.03
$25.56
50-Day Range
$11.68
MA: $15.68
$25.02
52-Week Range
$11.00
Now: $25.03
$26.78
Volume216,806 shs
Average Volume99,772 shs
Market Capitalization$809.42 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Synthorx, Inc, a biopharmaceutical company, focuses on the development of cytokine Synthorin programs for the treatment of cancer and autoimmune disorders in the United States. The company's lead product candidate is THOR-707, a variant of recombinant human IL-2 that is in the development in various solid tumor types as a single agent and in combination with an immune checkpoint inhibitor. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:THOR
CUSIP88517530
Phone858-750-4700

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$6.72 per share

Profitability

Net Income$-56,610,000.00

Miscellaneous

Employees39
Market Cap$809.42 million
Next Earnings Date3/10/2020 (Estimated)
OptionableNot Optionable

Receive THOR News and Ratings via Email

Sign-up to receive the latest news and ratings for THOR and its competitors with MarketBeat's FREE daily newsletter.


Synthorx (NASDAQ:THOR) Frequently Asked Questions

What is Synthorx's stock symbol?

Synthorx trades on the NASDAQ under the ticker symbol "THOR."

How were Synthorx's earnings last quarter?

Synthorx Inc (NASDAQ:THOR) issued its quarterly earnings results on Tuesday, November, 5th. The medical instruments supplier reported ($0.38) EPS for the quarter, topping analysts' consensus estimates of ($0.50) by $0.12. View Synthorx's Earnings History.

When is Synthorx's next earnings date?

Synthorx is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Synthorx.

What price target have analysts set for THOR?

5 Wall Street analysts have issued 12-month price targets for Synthorx's shares. Their forecasts range from $21.00 to $35.00. On average, they expect Synthorx's stock price to reach $28.67 in the next twelve months. This suggests a possible upside of 14.5% from the stock's current price. View Analyst Price Targets for Synthorx.

What is the consensus analysts' recommendation for Synthorx?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Synthorx in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Synthorx.

What are Wall Street analysts saying about Synthorx stock?

Here are some recent quotes from research analysts about Synthorx stock:
  • 1. According to Zacks Investment Research, "Synthorx Inc. is a biopharmaceutical company which focuses on cancer and autoimmune disorders. The company's product pipeline consists of THOR-707, IL-2 autoimmune synthorin, IL-10 synthorin and IL-15 synthorin which are in clinical stage. Synthorx Inc. is based in La Jolla, CA. " (11/9/2019)
  • 2. HC Wainwright analysts commented, "Our 12-month, $30 price target on shares of Synthorx is based on a 12-year DCF-based, sum-of-the-parts analysis. Our DCF is driven by: beta of 1.5, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 10.0%, and tax rate of 15% beginning in FY 2029. We assign a 9% POS for THOR-707, which we anticipate could be developed in NSCLC, RCC, melanoma, and urothelial cancer. These indications together represent about 95% of our target with NSCLC being the biggest driver of valuation, elaborated upon subsequently." (5/1/2019)

Has Synthorx been receiving favorable news coverage?

News headlines about THOR stock have been trending very positive this week, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Synthorx earned a daily sentiment score of 4.0 on InfoTrie's scale. They also gave news stories about the medical instruments supplier a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Synthorx.

Are investors shorting Synthorx?

Synthorx saw a increase in short interest during the month of October. As of October 31st, there was short interest totalling 824,900 shares, an increase of 10.5% from the September 30th total of 746,400 shares. Based on an average daily volume of 76,000 shares, the short-interest ratio is currently 10.9 days. Currently, 3.8% of the shares of the stock are short sold. View Synthorx's Current Options Chain.

Who are some of Synthorx's key competitors?

What other stocks do shareholders of Synthorx own?

Who are Synthorx's key executives?

Synthorx's management team includes the folowing people:
  • Dr. Laura K. Shawver, CEO, Pres & Director (Age 61)
  • Dr. Floyd E. Romesberg, Scientific Founder & Director (Age 53)
  • Dr. Marcos Milla Ph.D., Chief Scientific Officer (Age 56)
  • Dr. Joseph Leveque, Chief Medical Officer (Age 58)
  • Terry L. Button, VP & Director

When did Synthorx IPO?

(THOR) raised $100 million in an IPO on Friday, December 7th 2018. The company issued 9,100,000 shares at $10.00-$12.00 per share. Jefferies, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Who are Synthorx's major shareholders?

Synthorx's stock is owned by a number of of institutional and retail investors. Top institutional investors include State Street Corp (0.45%), Russell Investments Group Ltd. (0.15%), First Trust Advisors LP (0.06%), California State Teachers Retirement System (0.05%) and Rhumbline Advisers (0.03%). Company insiders that own Synthorx stock include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Institutional Ownership Trends for Synthorx.

Which institutional investors are buying Synthorx stock?

THOR stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., State Street Corp, First Trust Advisors LP, Rhumbline Advisers and California State Teachers Retirement System. Company insiders that have bought Synthorx stock in the last two years include Orbimed Advisors Llc, Ra Capital Healthcare Fund Lp and Tighe Reardon. View Insider Buying and Selling for Synthorx.

How do I buy shares of Synthorx?

Shares of THOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Synthorx's stock price today?

One share of THOR stock can currently be purchased for approximately $25.03.

How big of a company is Synthorx?

Synthorx has a market capitalization of $809.42 million. The medical instruments supplier earns $-56,610,000.00 in net income (profit) each year or ($6.59) on an earnings per share basis. Synthorx employs 39 workers across the globe.View Additional Information About Synthorx.

What is Synthorx's official website?

The official website for Synthorx is http://www.synthorx.com/.

How can I contact Synthorx?

Synthorx's mailing address is 11099 North Torrey Pines Road Suite 190, La Jolla CA, 92037. The medical instruments supplier can be reached via phone at 858-750-4700 or via email at [email protected]


MarketBeat Community Rating for Synthorx (NASDAQ THOR)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  399 (Vote Outperform)
Underperform Votes:  429 (Vote Underperform)
Total Votes:  828
MarketBeat's community ratings are surveys of what our community members think about Synthorx and other stocks. Vote "Outperform" if you believe THOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe THOR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/7/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel